Jenny Bryant, executive vice president of policy, research and membership, Pharmaceutical Research and Manufacturers of America
Steve Anderson: Government leadership is sorely needed to ensure pharmacies can continue to be there for Americans in times of need from family emergencies to global pandemics. Much has been made of the statement: “There is a pharmacy within 5 miles of 90% of Americans.” However, unworkable and unsustainable pharmacy reimbursement models, which jeopardize pharmacies of all sizes and formats, risk the public health assets that came through when the nation needed them most.
Even as the industry advocates for the public policy that is needed for pharmacies’ viability and to leverage their full value for all Americans, the industry continues to innovate.
Douglas Hoey: The CPESN USA clinically integrated network of pharmacies is a solution and in many ways is the future of pharmacy. It improves quality, lowers costs and can negotiate pharmacy provider services with payers, as opposed to the middlemen who continue to make things difficult for independent pharmacies and patients alike.
Among our priorities has been ending retroactive pharmacy DIR fees. With a recent rule proposed by the Centers for Medicare and Medicaid Services, we’re closer than ever to accomplishing that goal.
There’s a lot to do to ensure the best possible rule is finalized for plan year 2023. We will be working with our partners, members and champions in Congress toward that end, and to continue changing the pharmacy payment model.
Jenny Bryant: As treatments for COVID shift from hospital administration to more accessible retail options, many patients will have the convenience of going to their local pharmacy to pick up their prescriptions. Pharmacies will continue to play a significant role in helping to end this pandemic by providing the first line of treatment against the disease.
Mike McBride: Technology, again, will be key. Pharmacists are finding new ways to monetize the dispensing of care.
In general, the future will be bright for those who are willing to innovate and collaborate well with others. But overall, pharmacists will continue to benefit from their unique, historic relationship with patients.